Showing results (101-110 of 195) with videos related to

Sort By:
Pageof 20
Journal of Microbiology, Immunology, and Infection = Wei Mian Yu Gan Ran Za Zhi|September 2, 2004
An open study of inactivated hepatitis A vaccine (VAQTA) in Taiwanese healthy adult volunteers: safety, tolerability, and immunogenicityChin-Ying Yang, Chun-Yi Lu, Chin-Yun Lee, et al.
Vaccine|December 1, 2009
Disease burden and epidemiology of herpes zoster in pre-vaccine TaiwanYung-Hsiu Lin, Li-Min Huang, I-Shou Chang, et al.
Biotechnology Letters|December 18, 2004
Purification and characterisation of an alkaline protease used in tannery industry from Bacillus licheniformisXue-Ming Tang, F M Lakay, Wei Shen, et al.
Open Medicine (Warsaw, Poland)|March 14, 2023
Efficacy of immune checkpoint inhibitors in patients with KRAS-mutant advanced non-small cell lung cancer: A retrospective analysisXiaodong Gu, Jinfei Si, Yelan Guan, et al.
American Journal of Health Promotion : AJHP|April 13, 2024
Association Between the Improvement of Knowledge, Attitude and Practice of Hypertension Prevention and Blood Pressure Control-A Cluster Randomized Controlled StudyZhen Hu, Xin Wang, Congyi Zheng, et al.
Obesity (Silver Spring, Md.)|September 25, 2019
Prevalence of Abdominal Obesity in China: Results from a Cross-Sectional Study of Nearly Half a Million ParticipantsLinfeng Zhang, Zengwu Wang, Xin Wang, et al.
International Journal of Cardiology|November 4, 2018
A national study of the prevalence and risk factors associated with peripheral arterial disease from China: The China Hypertension Survey, 2012-2015Zengwu Wang, Xin Wang, Guang Hao, et al.
Chemical Communications (Cambridge, England)|July 4, 2025
Solid-state nanopore detection of metal ions via a DNAzyme-Catalytic Hairpin Assembly reactionYesheng Wang, Lan Shao, Chunmiao Yu, et al.
Cellular Immunology|October 19, 2023
ATM-AMPKα mediated LAG-3 expression suppresses T cell function in prostate cancerXinyao Zhang, Haiqi Chen, Jiawen Han, et al.
Cancer Medicine|September 5, 2025
An Open-Label, Single-Arm, Phase II Trial of Sintilimab Plus Anlotinib for Metastatic Non-Small Cell Lung Cancer After First-Line PD-(L)1 InhibitorXun Shi, Chen Lin, Lishu Lou, et al.
Pageof 20